Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Liabilities (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Total Liabilities for 6 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 15.51% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.7 million through Dec 2025, up 15.51% year-over-year, with the annual reading at $44.7 million for FY2025, 15.51% up from the prior year.
  • Total Liabilities for Q4 2025 was $44.7 million at Janux Therapeutics, down from $48.2 million in the prior quarter.
  • The five-year high for Total Liabilities was $48.2 million in Q3 2025, with the low at $12.0 million in Q2 2021.
  • Average Total Liabilities over 5 years is $33.7 million, with a median of $38.5 million recorded in 2024.
  • Peak annual rise in Total Liabilities hit 245.45% in 2022, while the deepest fall reached 25.38% in 2022.
  • Over 5 years, Total Liabilities stood at $13.5 million in 2021, then skyrocketed by 220.59% to $43.3 million in 2022, then dropped by 16.67% to $36.1 million in 2023, then increased by 7.42% to $38.7 million in 2024, then rose by 15.51% to $44.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $44.7 million, $48.2 million, and $41.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.